Breaking News
Get 50% Off 0
🏄 Grow your portfolio even on vacation with InvestingPro | Summer Sale 50% OFF
CLAIM SALE
Close

Acumen Pharmaceuticals Inc (ABOS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Acumen Pharmaceuticals's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.420 +0.060    +4.41%
11/08 - Closed. Currency in USD
After Hours
1.420
0.000
0.000%
0:52:35 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 418,750
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.360 - 1.500
Acumen Pharmaceuticals 1.420 +0.060 +4.41%

Acumen Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Acumen Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

61

Equity Type

ORD

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Contact Information

Address 1210-1220 Washington St. Suite 210
Newton, 02465
United States
Phone 617 344 4190
Fax -

Top Executives

Name Age Since Title
Jeffrey L. Cummings 75 - Member of Clinical & Scientific Advisory Board
Laura Stoppel 39 2020 Independent Director
Reisa Sperling - - Member of Clinical & Scientific Advisory Board
Nathan B. Fountain 61 2021 Independent Director
Lennart Mucke - 2022 Member of the Scientific Advisory Board
Daniel J. O'Connell 54 2006 CEO & Director
Cynthia A. Lemere - - Member of Clinical & Scientific Advisory Board
Colin Louis Masters 78 - Member of Clinical & Scientific Advisory Board
Stephen Salloway - - Member of Clinical & Scientific Advisory Board
Jeffrey L. C. Ives 74 2014 Independent Director
Michael A. Weiner 78 - Member of Clinical & Scientific Advisory Board
Derrell D. Porter 53 2023 Independent Director
Sean Stalfort 55 2018 Independent Chairman of the Board
Steven T. DeKosky - - Member of Clinical & Scientific Advisory Board
Kimberlee Cobleigh Drapkin 57 2022 Independent Director
Dominic Walsh - 2025 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ABOS Comments

Write your thoughts about Acumen Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email